Improvement of prognosis for unresectable biliary tract cancer

World Journal of Gastroenterology

Volumn 19, Issue 1, 2013, Pages 72-77

  Sasaki, Takashi ^a   Isayama, Hiroyuki ^a   Nakai, Yousuke ^a   Takahara, Naminatsu ^a   Sasahira, Naoki ^a   Kogure, Hirofumi ^a   Mizuno, Suguru ^b   Yagioka, Hiroshi ^c   Ito, Yukiko ^d   Yamamoto, Natsuyo ^a   Hirano, Kenji ^a   Toda, Nobuo ^e   Tada, Minoru ^a   Omata, Masao ^f   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Mutual Aid Association of Public School Teachers   (Japan)

^c JR Tokyo General Hospital   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f Yamanashi Prefectural Central Hospital   (Japan)

Author keywords

Biliary tract cancer; Fluoropyrimidine; Gemcitabine; Platinum analogs; Unresectable

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MITOMYCIN; PLATINUM DERIVATIVE; UFT;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84873649472     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i1.72     Document Type: Article

References (16)

1. Tada M, Nakai Y, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Omata M, Koike K. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2011; 2: 158-163. [PMID: 21611090 DOI: 10.5306/wjco.v2.i3.158]
2. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902. [PMID: 17325704 DOI: 10.1038/ sj.bjc.6603648]
3. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37: 843-851. [PMID: 17942578 DOI: 10.1093/jjco/ hym116]
4. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T. Phase II study of singleagent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57: 647-653. [PMID: 16142487 DOI: 10.1007/s00280-005-0095-3]
5. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91: 1769-1774. [PMID: 15505626 DOI: 10.1038/sj.bjc.6602208]
6. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008; 62: 849-855. [PMID: 18214482 DOI: 10.1007/s00280-007-0673-7]
7. Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T, Togawa O, Matsubara S, Ito Y, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M. S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 2009; 77: 71-74. [PMID: 19556812 DOI: 10.1159/000226214]
8. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012; 30: 708-713. [PMID: 20924641 DOI: 10.1007/ s10637-010-9553-9]
9. Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010; 65: 1101-1107. [PMID: 19707761 DOI: 10.1007/s00280-009-1115-5]
10. Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2011; 67: 1429-1434. [PMID: 20811895 DOI: 10.1007/ s00280-010-1443-5]
11. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281. [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]
12. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474. [PMID: 20628385 DOI: 10.1038/sj.bjc.6605779]
13. Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol 2011; 67: 847-853. [PMID: 20563811 DOI: 10.1007/s00280-010-1360-7]
14. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Kanda J, Wakabayashi H, Hatakeyama K. [Effect of pyloruspreserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy]. Gan To Kagaku Ryoho 2010; 37: 1503-1506. [PMID: 20716875]
15. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011; 29: 1488-1493. [PMID: 20607585 DOI: 10.1007/s10637-010-9485-4]
16. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423. [PMID: 18448556 DOI: 10.1634/theoncologist.2007-0252]